Company to present, across eight data
presentations, new real-world research on the economic value of
genetic testing for retinal diseases and the role of automatic
deep-learning based algorithms for geographic
atrophy
Johnson & Johnson to debut
first-of-its-kind EYE-RD Global Registry, aiming to bridge
knowledge gaps for inherited retinal diseases
RARITAN,
N.J., May 3, 2024
/PRNewswire/ -- Johnson &
Johnson today announced that eight company-sponsored presentations
will be featured during the Association for
Research in Vision and Ophthalmology (ARVO) 2024 Annual
Meeting taking place in Seattle from May 5–9, 2024. The Company's two
oral presentations will include one highlighting a real-world
analysis on the economic value of early genetic testing in patients
with inherited retinal diseases (IRDs), a group of rare eye
disorders that can lead to serious vision impairment (Abstract
#2154), and the second
evaluating the role of automatic deep-learning based algorithms to
measure precursors of geographic atrophy (GA), a late-stage and
severe form of age-related macular degeneration (AMD) (Abstract
#2770).1,2
Experience the full interactive Multichannel News Release
here:
https://www.multivu.com/players/English/9259651-johnson-and-johnson-commits-to-transform-retinal-diseases-treatment-arvo-2024/
Additionally, Johnson & Johnson will spotlight its
EYE-RD Global Registry at the meeting, a first-of-its-kind
observational, non-interventional global IRD registry created to
make clinical information on IRDs more accessible to patients,
providers, payers, and researchers. The registry will serve as a
centralized repository of longitudinal data collected on
genetically tested patients who are diagnosed or have a suspected
diagnosis of IRDs such as X-linked retinitis pigmentosa, a rare IRD
estimated to impact one in 40,000 people
globally.3,4 The registry has the
potential to bridge the knowledge gap in IRDs through the
collection of real-world data by collating more holistic insights
about disease progression and patient experiences.
"At Johnson & Johnson, we are committed to preserving
vision, harnessing the best science to find solutions for those
living with blinding retinal diseases," said Hideo Makimura, M.D., Ph.D., Vice President and
Global Head, Specialty Ophthalmology Research and Development,
Johnson & Johnson Innovative Medicine. "These data at ARVO 2024
showcase our commitment to bringing innovative new therapies that
preserve and restore vision for patients worldwide."
Key results from two oral presentations
include:
- Economic Value of Early Genetic Testing in Inherited
Retinal Dystrophies Diagnosis (Abstract
#2154)1
- Patients with delayed genetic testing incurred
significantly higher healthcare costs than those with early genetic
testing ($76,838 vs. $13,084 in total costs,
respectively).
- Genetic testing is often delayed due to lack of awareness
or cost. The data reinforces the importance of early testing to
potentially help improve IRD diagnosis and lower overall healthcare
costs.
- Deep-Learning Based Algorithm for Automatic cRORA and
Photoreceptor Loss Detection in Spectral Domain Optical Coherence
Tomography (SD-OCT) Imaging (Abstract
#2770)2
- Due to slow and variable GA progression in patients, it
can be challenging to measure the efficacy of treatments in
clinical trials, often leading to long trial durations and large
sample sizes, which could delay the availability of potential new
therapies.
- Automatic deep-learning based segmentation of multiple
SD-OCT imaging biomarkers could potentially provide a time-saving
and cost-effective method to quantify and predict disease
progression and help clinicians more rapidly determine the efficacy
of treatments in clinical trials.
A complete listing of the Company-sponsored abstracts
being featured at the ARVO Annual Meeting is provided below.
Abstracts can also be found on the
ARVO website.
Presentation /
Poster #
|
Title
|
Abstract
#2154
|
Economic Value of Early
Genetic Testing in Inherited Retinal Dystrophies
Diagnosis.
|
Abstract #2283
Posterboard
#A0137
|
Comparison of FAF and
SD-OCT Geographic Atrophy Lesion Area and
Growth Rate Measurements.
|
Abstract
#2580
Posterboard
#B0207
|
Individuals With
Geographic Atrophy (GA) Are at Greater Risk for Fall and
Fracture Events Compared to Individuals Without GA: A US Claims
Data
Analysis.
|
Abstract #3110
Posterboard
#A0374
|
The Patient Journey
from Early Symptoms to Initial Diagnosis of RPGR-
Associated Retinal Disease: Can We Shorten Time to First Diagnosis
in a
Gene Therapy Era?
|
Abstract #3739
Posterboard
#B0402
|
Using Artificial
Intelligence (AI) to Identify and Characterize RPGR Patients
in a Large Electronic Health Record (EHR) Database.
|
Abstract #3112
Posterboard
#A0376
|
Decline Of Visual
Function and Risk of Legal Blindness with Age in Patients
With RPGR-Associated Retinal Degeneration, A Multicenter
Study.
|
Abstract #2770
|
Deep-Learning Based
Algorithm for Automatic cRORA and Photoreceptor
Loss Detection in SD-OCT Imaging.
|
Abstract
#5984
Posterboard
#B0647
|
Individuals with
Geographic Atrophy (GA) Are at Greater Risk for Anxiety
Disorder and Depression Compared to Individuals Without GA: A
US
Claims Data Analysis.
|
Johnson & Johnson will also have an interactive
Specialty Ophthalmology Medical Affairs exhibit booth (location
#1539) at the ARVO annual meeting. For more information about
Johnson & Johnson's investigational portfolio in Specialty
Ophthalmology, please
visit www.retina.janssen.com.
About Our Commitment to Eye Health
At Johnson & Johnson, we have a deep legacy in developing
transformational new products that improve the health of patients'
eyes. As a global leader in eye health, we have a bold ambition:
Vision Made Possible – and are paving the way for a new future of
eye health to support the full spectrum of pediatric, developed,
and mature eyes. Through cutting-edge innovation, scientific
expertise, and advanced technologies, we are revolutionizing the
way people see and experience the world. At every step of the eye
health journey – from investigational gene therapies for retinal
diseases to contact lenses and refractive and cataract surgical
solutions – we stand as a trusted partner with the goal of making
vision possible for customers and patients.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our
strength in healthcare innovation empowers us to build a world
where complex diseases are prevented, treated, and cured, where
treatments are smarter and less invasive, and solutions are
personal. Through our expertise in Innovative Medicine and MedTech,
we are uniquely positioned to innovate across the full spectrum of
healthcare solutions today to deliver the breakthroughs of
tomorrow, and profoundly impact health for humanity.
Learn more
at www.jnj.com or
at www.janssen.com/johnson-johnson-innovative-medicine.
Follow us
at @JanssenUS and @JNJInnovMed.
Janssen Research & Development, LLC is a Johnson & Johnson
company.
Cautions Concerning Forward-Looking
Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding product development and the potential benefits and
treatment impact of botaretigene sparoparvovec and JNJ-81201887.
The reader is cautioned not to rely on these forward-looking
statements. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Janssen
Research & Development, LLC, Janssen Biotech, Inc. and/or
Johnson & Johnson. Risks and uncertainties include, but are not
limited to: challenges and uncertainties inherent in product
research and development, including the uncertainty of clinical
success and of obtaining regulatory approvals; uncertainty of
commercial success; manufacturing difficulties and delays;
competition, including technological advances, new products and
patents attained by competitors; challenges to patents; product
efficacy or safety concerns resulting in product recalls or
regulatory action; changes in behavior and spending patterns of
purchasers of health care products and services; changes to
applicable laws and regulations, including global health care
reforms; and trends toward health care cost containment. A further
list and descriptions of these risks, uncertainties and other
factors can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended December
31, 2023, including in the sections captioned "Cautionary
Note Regarding Forward-Looking Statements" and "Item 1A. Risk
Factors," and in Johnson & Johnson's subsequent Quarterly
Reports on Form 10-Q and other filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request from Johnson &
Johnson. Neither Janssen Research & Development, LLC nor
Johnson & Johnson undertake to update any forward-looking
statement as a result of new information or future events or
developments.
© Johnson & Johnson, Inc. 2024. All rights
reserved.
Media Contact:
Rachael
Jarnagin
rjarnagi@its.jnj.com
+1 415 705 9023
Investor contact:
Raychel
Kruper
investor-relations@its.jnj.com
1 Zhang Q, et al. Economic value of early
genetic testing in inherited retinal dystrophies diagnosis.
Abstract #2154. Association for Research in Vision and
Ophthalmology 2024 Annual
Meeting
2 De Silva T, et al. Deep
Learning based Algorithm for Automatic cRORA and Photoreceptor Loss
Detection in SD-OCT Imaging. Abstract #2770. Association for
Research in Vision and Ophthalmology 2024 Annual
Meeting
3 Boughman JA, Conneally
PM, Nance WE. Population genetic studies of retinitis
pigmentosa. Am J Hum
Genet. 1980;32(2):223–235.
4 Fishman
GA. Retinitis pigmentosa. Genetic percentages. Arch
Ophthalmol. 1978;96(5):822–826.
PDF:
https://www.multivu.com/players/English/9259651-johnson-and-johnson-commits-to-transform-retinal-diseases-treatment-arvo-2024/docs/HandoutPDF_1714430004055-1892131328.pdf
View original
content:https://www.prnewswire.com/news-releases/johnson--johnson-highlights-commitment-to-transform-treatment-of-retinal-diseases-at-arvo-2024-302135329.html
SOURCE Johnson & Johnson Innovative Medicine